Paul Faduola, Alan Hakim, Juli Mansnerus, Atsuko Imai, Rob O Neill
Over 300 innovative biologic products have been tested for more than 200 diseases a pointer to the revolution in biotech companies to cure complex diseases. This surge in the development of biologics by biopharmaceutical industry which represents one of the fastest growing segments of U.S. healthcare have drawn attention to regulations aimed at protecting the public but they may also create barriers to market entry for new drugs. Several countries have therefore produced policies aimed at encouraging pharmaceutical and biotechnological companies to develop innovative drugs that are in serious demand in the society. An example of this policy is the Orphan Drug Act which offers exclusive marketing rights, grant support, tax credits for certain clinical development expenses and other incentives for sponsors to develop drugs for rare diseases . The objective of this paper is to describe the regulatory frameworks pertinent, though not necessarily specific to monoclonal antibodies Gemtuzumab Ozogamicin (“Gemtuzumab” or “Mylotarg”) and to outlined the key regulatory and compliance aspects for drug development and dissemination.
English 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi